In this study, 26 patients with advanced melanoma were treated locally by ILI with the nitrogen mustard-alkylating agent melphalan, followed by the systemic administration of CTLA-4 blocking the antibody (ipilimumab) in a phase II trial. The gene discussed is CTLA4; the disease is melanoma.